A veteran biopharma executive and experienced scientist with over 30 years in biotech, Glucksmann most recently served as founding CEO and President of Cedilla Therapeutics and previously was founding Chief Operating Officer of Editas Medicine, Inc. She serves on the boards of directors of gene therapy company REGENXBIO and and genetic modifiers company Scenic Biotech. Alexandra holds a Ph.D. with honors in molecular genetics and cell biology from the University of Chicago.